CAR-T cells and solid tumors: Tuning T cells to challenge an inveterate foe

Trends in Molecular Medicine

Volumn 18, Issue 7, 2012, Pages 377-384

  Gilham, David E ^a   Debets, Reno ^b   Pule, Martin ^c   Hawkins, Robert E ^a   Abken, Hinrich ^d,e  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^e UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Adoptive cell therapy; Cancer; Chimeric antigen receptor; Gene transfer; Immunotherapy; T cell

Indexed keywords

CARBONATE DEHYDRATASE IX; CD137 ANTIGEN; CD19 ANTIGEN; CD28 ANTIGEN; CD3 ANTIGEN; CHIMERIC PROTEIN; FOLATE RECEPTOR 1; INTERLEUKIN 2; LENTIVIRUS VECTOR; LYMPHOCYTE ANTIGEN RECEPTOR; PLASMID DNA; TRANSFORMING GROWTH FACTOR BETA; TUMOR ANTIGEN;

ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; B CELL LEUKEMIA; CD8+ T LYMPHOCYTE; CELL ENGINEERING; CELL MANIPULATION; CELL POPULATION; CELL PROLIFERATION; CELL THERAPY; CHOLANGITIS; CHRONIC LYMPHATIC LEUKEMIA; DNA TRANSFER; ENGRAFTMENT; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IN VIVO STUDY; KIDNEY CARCINOMA; LYMPHOMA; MAJOR HISTOCOMPATIBILITY COMPLEX; MORTALITY; NONHUMAN; OVARY CARCINOMA; REGULATORY T LYMPHOCYTE; REVIEW; RNA TRANSPORT; SOLID TUMOR; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TRANSPOSON; VIRAL GENE DELIVERY SYSTEM;

ADOPTIVE TRANSFER; ANIMALS; ANTIGENS, NEOPLASM; HUMANS; NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES;

EID: 84863085396     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2012.04.009     Document Type: Review

References (70)

1. Elkord E., et al. Immune evasion mechanisms in colorectal cancer liver metastasis patients vaccinated with TroVax (MVA-5T4). Cancer Immunol. Immunother. 2009, 58:1657-1667.
2. Garrido F., et al. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol. Today 1997, 18:89-95.
3. Pule M.A., et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat. Med. 2008, 14:1264-1270.
4. Louis C.U., et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood 2011, 118:6050-6056.
5. Kalos M., et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci. Transl. Med. 2011, 3:95ra73.
6. Porter D.L., et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 2011, 365:725-733.
7. Brentjens R.J., et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 2011, 118:4817-4828.
8. Kochenderfer J.N., et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 2012, 119:2709-2720.
9. Kochenderfer J.N., et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 2010, 116:4099-4102.
10. Gross G., Eshhar Z. Endowing T cells with antibody specificity using chimeric T cell receptors. FASEB J. 1992, 6:3370-3378.
11. Gross G., et al. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc. Natl. Acad. Sci. U.S.A. 1989, 86:10024-10028.
12. Bridgeman J.S., et al. Building better chimeric antigen receptors for adoptive T cell therapy. Curr. Gene Ther. 2010, 10:77-90.
13. Jena B., et al. Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor. Blood 2010, 116:1035-1044.
14. Kalos M. Muscle CARs and TcRs: turbo-charged technologies for the (T cell) masses. Cancer Immunol. Immunother. 2012, 61:127-135.
15. Darcy P.K., et al. Expression in cytotoxic T lymphocytes of a single-chain anti-carcinoembryonic antigen antibody. Redirected Fas ligand-mediated lysis of colon carcinoma. Eur. J. Immunol. 1998, 28:1663-1672.
16. Gilham D.E., et al. Primary polyclonal human T lymphocytes targeted to carcino-embryonic antigens and neural cell adhesion molecule tumor antigens by CD3zeta-based chimeric immune receptors. J. Immunother. 2002, 25:139-151.
17. Finney H.M., et al. Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product. J. Immunol. 1998, 161:2791-2797.
18. Hombach A., et al. Tumor-specific T cell activation by recombinant immunoreceptors: CD3 zeta signaling and CD28 costimulation are simultaneously required for efficient IL-2 secretion and can be integrated into one combined CD28/CD3 zeta signaling receptor molecule. J. Immunol. 2001, 167:6123-6131.
19. Haynes N.M., et al. Rejection of syngeneic colon carcinoma by CTLs expressing single-chain antibody receptors codelivering CD28 costimulation. J. Immunol. 2002, 169:5780-5786.
20. Hombach A.A., Abken H. Costimulation by chimeric antigen receptors revisited the T cell antitumor response benefits from combined CD28-OX40 signalling. Int. J. Cancer 2011, 129:2935-2944.
21. Carpenito C., et al. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:3360-3365.
22. Milone M.C., et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol. Ther. 2009, 17:1453-1464.
23. Song D.G., et al. In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB). Cancer Res. 2011, 71:4617-4627.
24. Kershaw M.H., et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin. Cancer Res. 2006, 12:6106-6115.
25. Lamers C.H., et al. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J. Clin. Oncol. 2006, 24:e20-e22.
26. Lamers C.H., et al. Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells. Blood 2011, 117:72-82.
27. Morgan R.A., et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol. Ther. 2010, 18:843-851.
28. Brentjens R., et al. Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial. Mol. Ther. 2010, 18:666-668.
29. Dudley M.E., et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J. Clin. Oncol. 2008, 26:5233-5239.
30. Till B.G., et al. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood 2008, 112:2261-2271.
31. + T cells derived from central memory cells establishes persistent T cell memory in primates. J. Clin. Invest. 2008, 118:294-305.
32. + T cells mediate superior antitumor immunity. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:17469-17474.
33. + T-cell adoptive immunotherapy for large established tumors in mice. Clin. Cancer Res. 2011, 17:5343-5352.
34. Gattinoni L., et al. A human memory T cell subset with stem cell-like properties. Nat. Med. 2011, 17:1290-1297.
35. Bondanza A., et al. Suicide gene therapy of graft-versus-host disease induced by central memory human T lymphocytes. Blood 2006, 107:1828-1836.
36. Duarte R.F., et al. Functional impairment of human T-lymphocytes following PHA-induced expansion and retroviral transduction: implications for gene therapy. Gene Ther. 2002, 9:1359-1368.
37. Pouw N., et al. TCR gene-engineered T cell: limited T cell activation and combined use of IL-15 and IL-21 ensure minimal differentiation and maximal antigen-specificity. Mol. Immunol. 2010, 47:1411-1420.
38. Newrzela S., et al. Resistance of mature T cells to oncogene transformation. Blood 2008, 112:2278-2286.
39. Newrzela S., et al. Retroviral insertional mutagenesis can contribute to immortalization of mature T lymphocytes. Mol. Med. 2010, 17:1223-1232.
40. Miller D.G., et al. Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection. Mol. Cell. Biol. 1990, 10:4239-4242.
41. Frecha C., et al. Advances in the field of lentivector-based transduction of T and B lymphocytes for gene therapy. Mol. Ther. 2010, 18:1748-1757.
42. Gilham D.E., et al. Cytokine stimulation and the choice of promoter are critical factors for the efficient transduction of mouse T cells with HIV-1 vectors. J. Gene Med. 2010, 12:129-136.
43. Cooper L.J., et al. Manufacturing of gene-modified cytotoxic T lymphocytes for autologous cellular therapy for lymphoma. Cytotherapy 2006, 8:105-117.
44. Jensen M.C., et al. Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans. Biol. Blood Marrow Transplant. 2010, 16:1245-1256.
45. Van den Driessche T., et al. Emerging potential of transposons for gene therapy and generation of induced pluripotent stem cells. Blood 2009, 114:1461-1468.
46. Kebriaei P., et al. Infusing CD19-directed T cells to augment disease control in patients undergoing autologous hematopoietic stem-cell transplantation for advanced B-lymphoid malignancies. Hum. Gene Ther. 2012, 10.1089/hum.2011.167.
47. + T cells for use in the adoptive immunotherapy of cancer. Gene Ther. 2009, 16:596-604.
48. Zhao Y., et al. Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor. Cancer Res. 2010, 70:9053-9061.
49. Barrett D.M., et al. Treatment of advanced leukemia in mice with mRNA engineered T cells. Hum. Gene Ther. 2011, 22:1575-1586.
50. Kaneko S., et al. IL-7 and IL-15 allow the generation of suicide gene-modified alloreactive self-renewing central memory human T lymphocytes. Blood 2009, 113:1006-1015.
51. Pouw N., et al. Combination of IL-21 and IL-15 enhances tumour-specific cytotoxicity and cytokine production of TCR-transduced primary T cells. Cancer Immunol. Immunother. 2010, 59:921-931.
52. Kalamasz D., et al. Optimization of human T-cell expansion ex vivo using magnetic beads conjugated with anti-CD3 and anti-CD28 antibodies. J. Immunother. 2004, 27:405-418.
53. Suhoski M.M., et al. Engineering artificial antigen-presenting cells to express a diverse array of co-stimulatory molecules. Mol. Ther. 2007, 15:981-988.
54. Sadeghi A., et al. Large-scale bioreactor expansion of tumor-infiltrating lymphocytes. J. Immunol. Methods 2011, 364:94-100.
55. Kershaw M.H., et al. Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2. Hum. Gene Ther. 2002, 13:1971-1980.
56. Craddock J.A., et al. Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b. J. Immunother. 2010, 33:780-788.
57. + T cells in an antitumor cell attack. Cancer Res. 2007, 67:2265-2273.
58. Kofler D.M., et al. CD28 costimulation impairs the efficacy of a redirected T-cell antitumor attack in the presence of regulatory T cells which can be overcome by preventing Lck activation. Mol. Ther. 2011, 19:760-767.
59. Chmielewski M., et al. IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively Muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression. Cancer Res. 2011, 71:5697-5706.
60. Zhang L., et al. Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment. Mol. Ther. 2011, 19:751-759.
61. Chmielewski M., Abken H. CAR T cells transform to trucks: chimeric antigen receptor-redirected T cells engineered to deliver inducible IL-12 modulate the tumour stroma to combat cancer. Cancer Immunol. Immunother. 2012, 10.1007/s00262-012-1202-z.
62. Hawkins R.E., et al. Development of adoptive cell therapy for cancer: a clinical perspective. Hum. Gene Ther. 2010, 21:665-672.
63. Schmidt P., Abken H. The beating heart of melanomas: a minor subset of cancer cells sustains tumor growth. Oncotarget 2011, 2:313-320.
64. Schmidt P., et al. Eradication of melanomas by targeted elimination of a minor subset of tumor cells. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:2474-2479.
65. Guest R.D., et al. The role of extracellular spacer regions in the optimal design of chimeric immune receptors: evaluation of four different scFvs and antigens. J. Immunother. 2005, 28:203-211.
66. Hombach A.A., et al. T cell activation by antibody-like immunoreceptors: the position of the binding epitope within the target molecule determines the efficiency of activation of redirected T cells. J. Immunol. 2007, 178:4650-4657.
67. Bridgeman J.S., et al. The optimal antigen response of chimeric antigen receptors harboring the CD3zeta transmembrane domain is dependent upon incorporation of the receptor into the endogenous TCR/CD3 complex. J. Immunol. 2010, 184:6938-6949.
68. Disis M.L. Immune regulation of cancer. J. Clin. Oncol. 2010, 28:4531-4538.
69. Whiteside T.L. Immune responses to malignancies. J. Allergy Clin. Immunol. 2010, 125:S272-S283.
70. Kandalaft L.E., et al. Endothelin B receptor, a new target in cancer immune therapy. Clin. Cancer Res. 2009, 15:4521-4528.